Servier / Kaerus Bioscience Ltd.

Fragile X Syndrome

40K US cases/yr · $0M No approved disease-modifying therapies; symptomatic prescribing (stimulants, SSRIs, antipsychotics) ~$100-200M estimated annual off-label pharmacy spend · ~30-50% Share of males with FXS who meet criteria for autism spectrum disorder (comorbidity expanding addressable opportunity)

Disease Overview

Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and the most common single-gene cause of autism spectrum disorder. It results from a CGG-trinucleotide repeat expansion (>200 repeats) in the FMR1 gene on the X chromosome, silencing production of fragile X messenger ribonucleoprotein (FMRP) which normally regulates synaptic protein translation. Loss of FMRP causes excessive group 1 metabotropic glutamate receptor (mGluR5) signaling, BK channel dysfunction, and synaptic hyperexcitability that manifests as intellectual disability (IQ typically 40-70), autism spectrum features (~30-50% of males), anxiety, hyperactivity, seizures (10-20%), sensory hypersensitivity, and social-communication deficits. US prevalence is estimated at approximately 1 in 7,000 males and 1 in 11,000 females (fully affected), translating to roughly 40,000-50,000 affected Americans. There are no approved disease-modifying therapies; standard care is symptomatic (stimulants, SSRIs, antipsychotics, anticonvulsants). FDA has granted Orphan Drug and Rare Pediatric Disease designations to KER-0193. The deal represents Servier's first neurology/rare-neurodevelopmental asset outside its core oncology and hematology franchises.

Competitive Landscape

The Fragile X syndrome therapeutic landscape has no approved disease-modifying therapy after a decade of high-profile mGluR5 antagonist failures (Roche's basimglurant and Novartis's mavoglurant both failed Phase 2/3 in the mid-2010s). Current prescribing is entirely symptomatic and off-label: stimulants (methylphenidate, amphetamines for ADHD symptoms), SSRIs (sertraline, fluoxetine for anxiety), atypical antipsychotics (risperidone, aripiprazole for irritability), and anticonvulsants (for seizures). Active pipeline mechanisms include Tetra Therapeutics/Shionogi's zatolmilast (BPN14770, PDE4D inhibitor, Phase 3), Healx's HLX-0201 (repurposed gaboxadol), and gene therapy efforts at Ovid/Takeda and academic labs. KER-0193 differentiates as an oral small-molecule BK (large-conductance calcium-activated potassium) channel modulator, targeting the synaptic hyperexcitability hypothesis via a non-glutamatergic mechanism distinct from failed mGluR5 programs. BK channel modulation also has potential read-across to autism spectrum disorder broadly per Servier's expansion framing. As Servier's first neurology asset, this builds on its oncology/rare disease commercial infrastructure and extends into neurodevelopmental rare disease.